Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Nutt

Showing results (11-20 of 179) with videos related to

Pageof 18
Sort By:
Addiction (Abingdon, England)|September 8, 2011
Let not the best be the enemy of the goodDavid Nutt
Journal of Psychopharmacology (Oxford, England)|December 3, 2016
Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the futureDavid Nutt
EMBO Reports|February 18, 2014
Mind-altering drugs and research: from presumptive prejudice to a Neuroscientific Enlightenment?: Science & Society series on "Drugs and Science"David Nutt
Human Psychopharmacology|February 20, 2026
Medicines for Anxiety: A Hundred Years of Tranquillity and More to Come?David Nutt
Plos Biology|January 28, 2015
Illegal drugs laws: clearing a 50-year-old obstacle to researchDavid Nutt
Current Opinion in Pharmacology|January 31, 2012
Massive overuse or appropriate medical intervention? The modern-day use of antidepressantsDavid Nutt
Addiction (Abingdon, England)|July 21, 2010
Science and non-science in UK drug policyDavid Nutt
Journal of Psychopharmacology (Oxford, England)|January 27, 2005
Cannabis antagonists: a new era of social psychopharmacology?David Nutt
Journal of Evaluation in Clinical Practice|May 23, 2013
Addiction: lifestyle choice or medical diagnosis?David Nutt
BMJ (Clinical Research Ed.)|May 3, 2019
Why medical cannabis is still out of patients' reach-an essay by David NuttDavid Nutt
Pageof 18

Showing results (11-20 of 179) with videos related to

Sort By:
Pageof 18
Addiction (Abingdon, England)|September 8, 2011
Let not the best be the enemy of the goodDavid Nutt
Journal of Psychopharmacology (Oxford, England)|December 3, 2016
Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the futureDavid Nutt
EMBO Reports|February 18, 2014
Mind-altering drugs and research: from presumptive prejudice to a Neuroscientific Enlightenment?: Science & Society series on "Drugs and Science"David Nutt
Human Psychopharmacology|February 20, 2026
Medicines for Anxiety: A Hundred Years of Tranquillity and More to Come?David Nutt
Plos Biology|January 28, 2015
Illegal drugs laws: clearing a 50-year-old obstacle to researchDavid Nutt
Current Opinion in Pharmacology|January 31, 2012
Massive overuse or appropriate medical intervention? The modern-day use of antidepressantsDavid Nutt
Addiction (Abingdon, England)|July 21, 2010
Science and non-science in UK drug policyDavid Nutt
Journal of Psychopharmacology (Oxford, England)|January 27, 2005
Cannabis antagonists: a new era of social psychopharmacology?David Nutt
Journal of Evaluation in Clinical Practice|May 23, 2013
Addiction: lifestyle choice or medical diagnosis?David Nutt
BMJ (Clinical Research Ed.)|May 3, 2019
Why medical cannabis is still out of patients' reach-an essay by David NuttDavid Nutt
Pageof 18